BJMO - volume 16, issue 2, march 2022
D. Schrijvers MD, PhD, S. Van Wambeke MD, W. Teurfs MD
The treatment of mRCC has undergone a tremendous evolution in the last decades. There are data that the doublets of checkpoints inhibitors with each other or with anti-angiogenic agents improve PFS compared to sunitinib alone.
In this article, we review the different combinations and give some guidance for their use.
(BELG J MED ONCOL 2022;16(2):48–52)
BJMO - volume 15, issue 6, october 2021
D. Schrijvers MD, PhD, W. Teurfs MD, S. Van Wambeke MD
BRCA mutations play an important role in prostate cancer. All patients with high-risk localised or metastatic prostate cancer should be tested for somatic mutations and, if present, for germline mutations. BRCA muta-tions translate in a more aggressive prostate cancer with a worse prognosis. If these mutations are present, PARP inhibitors may be part of the treatment strategy.
(BELG J MED ONCOL 2021;15(6):283-5)